Martingale Asset Management L P Purchases 13,719 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Martingale Asset Management L P raised its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 65.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,740 shares of the specialty pharmaceutical company's stock after buying an additional 13,719 shares during the period. Martingale Asset Management L P owned 0.17% of ANI Pharmaceuticals worth $2,073,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals by 1.8% in the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock valued at $32,005,000 after buying an additional 9,500 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new position in shares of ANI Pharmaceuticals during the second quarter worth approximately $600,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of ANI Pharmaceuticals during the second quarter worth approximately $228,000. Boston Partners bought a new stake in shares of ANI Pharmaceuticals during the first quarter valued at approximately $606,000. Finally, Thompson Siegel & Walmsley LLC increased its holdings in shares of ANI Pharmaceuticals by 17.6% in the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock valued at $13,731,000 after purchasing an additional 34,416 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ANIP has been the topic of a number of recent research reports. StockNews.com lowered ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. HC Wainwright reiterated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an "overweight" rating and a $68.00 price objective for the company. Raymond James upped their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research report on Wednesday, September 18th. Finally, Truist Financial raised their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research note on Tuesday, October 22nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $77.33.

Insider Activity

In related news, CEO Nikhil Lalwani sold 33,481 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at approximately $21,478,220.22. The trade was a 8.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 33,981 shares of company stock valued at $1,970,066 in the last quarter. Company insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Trading Down 3.6 %

ANIP traded down $2.16 during midday trading on Friday, reaching $57.23. 224,908 shares of the company were exchanged, compared to its average volume of 290,745. The stock has a market capitalization of $1.20 billion, a P/E ratio of -104.05 and a beta of 0.71. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81. The stock's 50-day simple moving average is $58.22 and its 200 day simple moving average is $60.64. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.05 EPS. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.